Skip to main content
SpringerLink
Log in

Glycemic targets in diabetes

  • Review Article
  • Published:
International Journal of Diabetes in Developing Countries Aims and scope Submit manuscript

Abstract

Target setting is an important strategy in diabetes. The commonly used glycemic targets are blood glucose and HbA1c. The target values can be fixed based upon normative data or outcome data. Individualization of glycemic targets is based upon age of patient, duration of diabetes, life expectancy, type of diabetes, type of therapy, presence of complications, propensity for hypoglycemia, hypoglycemia awareness, availability of family support, patient motivation, and patient education. Currently, the rate of attainment of glycemic target is improving, and almost 50 % of diabetics achieve HbA1C targets. In pregnancy, glycemic targets recommended are strict. Furthermore, the concept of individualization needs to be extended to the pregnant state. We propose that the glycemic targets in pregnancy with diabetes should be different in gestational diabetes, pre-gestational type 2 diabetes, and type 1 diabetes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Mikesh LM, Bruns DE. Stabilization of glucose in blood specimens: mechanism of delay in fluoride inhibition of glycolysis. Clin Chem. 2008;54:930–2.

    Article  CAS  PubMed  Google Scholar 

  2. Bruns DE, Knowler WC. Stabilization of glucose in blood samples: why it matters. Clin Chem. 2009;55:850–2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Chandalia HB, Krishnaswamy PR. Glycated hemoglobin. Curr Sci. 2002;83:1522–32.

    CAS  Google Scholar 

  4. Chandalia HB. Standardization of hemoglobin A1c. Int J Diab Dev Ctries. 2010;30:109–10.

    Article  Google Scholar 

  5. Rohlfing C, Wiedmeyer HM, Little R, et al. Biological variation of glycohemoglobin. Clin Chem. 2002;48:1116–8.

    CAS  PubMed  Google Scholar 

  6. Selvin E, Crainiceanu CM, Brancati FL, Coresh J. Short-term variability in measures of glycemia and implications for the classification of diabetes. Arch Intern Med. 2007;167:1545–51.

    Article  CAS  PubMed  Google Scholar 

  7. International HbA1c Consensus Committee. Consensus statement on the worldwide standardization of the hemoglobin A1c measurement. Diabetes Care. 2010;33:1903–4.

    Article  Google Scholar 

  8. Oliver NS, Toumazou C, Cass AEG, Johnston DG. Glucose sensors: a review of current and emerging technology. Diabet Med. 2009;26:197–210.

    Article  CAS  PubMed  Google Scholar 

  9. Hill NR, Oliver NS, Choudhary P, Levy JC, Hindmarsh P, Matthews DR. Normal reference range for mean tissue glucose and glycemic variability derived from continuous glucose monitoring for subjects without diabetes in different ethnic groups. Diabetes Technol Ther. 2011;13:921–8.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, Colette C. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA. 2006;295:1681–7.

  11. Strowig SM, Raskin P. Improved glycemic control in intensively treated type 1 diabetic patients using blood glucose meters with storage capability and computer-assisted analyses. Diabetes Care. 1998;21:1694–8.

    Article  CAS  PubMed  Google Scholar 

  12. Karter AJ, Ackerson LM, Darbinian JA, D’Agostino Jr RB, Ferrara A, Liu J, Selby JV. Self-monitoring of blood glucose levels and glycemic control: the Northern California Kaiser Permanente Diabetes registry. Am J Med. 2001;111:1–9.

    Article  CAS  PubMed  Google Scholar 

  13. Skyler JS. Diabetic complications: the importance of glucose control. Endocrinol Metab Clin N Am. 1996;25:243–54.

    Article  CAS  Google Scholar 

  14. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–86.

    Article  Google Scholar 

  15. Colagiuri S, Lee CM, Wong TY, et al. Glycemic thresholds for diabetes-specific retinopathy: implications for diagnostic criteria for diabetes. Diabetes Care. 2011;34:145–50.

    Article  PubMed  Google Scholar 

  16. Ramlo-Halsted BA, Edelman SV. The natural history of type 2 diabetes: practical points to consider in developing prevention and treatment strategies. Clinical Diabetes. 2000;18:80–4.

    Google Scholar 

  17. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med. 2000;342:381–9.

    Article  Google Scholar 

  18. The Diabetes Control and Complications Trials/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643–53.

    Article  Google Scholar 

  19. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–89.

    Article  CAS  PubMed  Google Scholar 

  20. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–53.

    Article  Google Scholar 

  21. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care. 2002;25:S33–49.

    Article  Google Scholar 

  22. Chandalia HB. Controversial question: how closely is it possible to treat type 2 diabetic patients to recommended therapeutic goals in daily clinical practice? Medicographia. 2002;24:46.

  23. Nathan DM, Buse JB, Davidson MB, et al. The American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for Study of Diabetes. Diabetes Care. 2009;32:193–203.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Handelsman Y, Bloomgarden ZT, Grunberger G, et al. American Association of Clinical Endocrinologists and American College of Endocrinology—clinical practice guidelines for developing a diabetes mellitus comprehensive care plan. Endocr Pract. 2015;21(suppl 1):1–87.

    Article  PubMed  PubMed Central  Google Scholar 

  25. IDF Clinical Guidelines Task Force. Global guideline for type 2 diabetes. International Diabetes Federation 2012, Brussels

  26. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2013 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes. 2013;37(suppl 1):S1–S212.

    Google Scholar 

  27. National Institute for Health and Care Excellence (NICE). Type 2 diabetes in adults: management. 2015. No: NG28

  28. ADVANCE Collaborative Group, Patel A, MacMohan S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–72.

    Article  Google Scholar 

  29. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Buse JB, Cushman WC, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-2559

  30. Duckworth W, Abraira C, Moritz T, Reda D, Emannele N, Reaven PD, Zieve FJ, Marks J, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129–39.

    Article  CAS  PubMed  Google Scholar 

  31. Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Howard BV, Kirkman MS, Kosiborod M, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE and VA Diabetes Trials. Diabetes Care. 2009;32:187–92.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Vijan S, Hofer T, Hayward R. Estimate benefits of glycemic control in microvascular complications in type 2 diabetes. Ann Intern Med. 1997;127:788–95.

    Article  CAS  PubMed  Google Scholar 

  33. Bethel M, Sloan F, Belsky D, et al. Longitudinal incidence and prevalence of adverse outcomes of diabetes mellitus in elderly patients. Arch Intern Med. 2007;167:921–7.

    Article  PubMed  Google Scholar 

  34. Davis A, Haller MJ, Miller K, et al. Residual C-peptide in patients 3-81 years from diagnosis of T1D: a T1D exchange study. Diabetes. 2013;62:A422.

    Google Scholar 

  35. Heinemann L, Weyer C, Rauhaus M, Heinrichs S, Heise T. Variability of the metabolic effect of soluble insulin and the rapid acting insulin analogue insulin aspart. Diabetes Care. 1998;21:1910–4.

    Article  CAS  PubMed  Google Scholar 

  36. Heise T, Nosek L, Ronn BB, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes. 2004;53:1614–20.

    Article  CAS  PubMed  Google Scholar 

  37. Donnelly LA, Morris AD, Frier BM, Ellis JD, Donnan PT, Durrant R, Band MM, Reekie G, Leese P. Frequency and predictors of hypoglycemia in type 1 and insulin-treated type 2 diabetes: a population-based study. Diabet Med. 2005;22:749–55.

    Article  CAS  PubMed  Google Scholar 

  38. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA. 1999;281:2005–12.

    Article  CAS  PubMed  Google Scholar 

  39. Chalmers J, Cooper ME. UKPDS and the legacy effect. N Engl J Med. 2008;359:1618–20.

    Article  CAS  PubMed  Google Scholar 

  40. Heinemann L, Nosek L, Kapitza C, Schweitzer MA, Krinelke L. Changes in basal insulin infusion rates with subcutaneous insulin infusion. Diabetes Care. 2009;32:1437–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Huang Z, Wan X, Liu J, Deng W, Chen A, Liu L, Liu J, Wei G, Li H, Fang D, Li Y. Short-term continuous subcutaneous insulin infusion combined with insulin sensitizers rosiglitazone, metformin or antioxidant alpha-lipoic acid in patients with newly diagnosed type 2 diabetes mellitus. Diabetes Technol Ther. 2013;15:859–69.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364–79.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. The DCCT Research Group. Adverse events and their association with treatment regimens in the diabetes control and complications trial. Diabetes Care. 1995;18:1415–27.

    Article  Google Scholar 

  44. Cryer PE. Hypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes. Diabetologia. 2002;45:937–48.

    Article  CAS  PubMed  Google Scholar 

  45. Chelliah YR. Ventricular arrhythmias associated with hypoglycaemia. Anaesth Intensive Care. 2000;28:698–700.

    CAS  PubMed  Google Scholar 

  46. Cryer PE. Severe hypoglycemia predicts mortality in diabetes. Diabetes Care. 2012;35:1814–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Adler GK, Bonyhay I, Failing H, Waring E, Dotson S, Freeman R. Antecedent hypoglycemia impairs autonomic cardiovascular function: implications for rigorous glycemic control. Diabetes. 2009;58:360–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Norris SL, Lau J, Smith SJ, Schmid CH, Engelgau MM. Self-management education for adults with type 2 diabetes: a meta-analysis of the effect on glycemic control. Diabetes Care. 2002;25:1159–71.

    Article  PubMed  Google Scholar 

  49. Williams MV, Baker DW, Parker RM, et al. Relationship of functional health literacy to patients’ knowledge of their chronic disease. A study of patients with hypertension and diabetes. Arch Int Med. 1998;158(2):166–72.

    Article  CAS  Google Scholar 

  50. Schillinger D, Grumbach K, Piette J, et al. Association of health literacy with diabetes outcomes. J Am Med Assoc. 2002;288:475–82.

    Article  Google Scholar 

  51. Hoerger TJ, Segel JE, Gregg EW, Saaddine JB. Is glycemic control improving in U.S. Adults? Diabetes Care. 2008;31:81–6.

    Article  PubMed  Google Scholar 

  52. Blumenthal KJ, Larkin ME, Winning G, Nathan DM, Grant RW. Changes in glycemic control from 1996 to 2006 among adults with type 2 diabetes: a longitudinal cohort study. BMC Health Serv Res. 2010;10:158.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Monnier L, Lapinski H, Colette C. Contributions of fasting and post-prandial plasma glucose increments to the overall diurnal hyperglycaemia of type 2 diabetic patients: variations with increasing levels of HbA1c. Diabetes Care. 2003;26:881–5.

    Article  PubMed  Google Scholar 

  54. Monnier L, Colette C, Dunseath GJ. The loss of postprandial glycaemic control precedes stepwise deterioration of fasting with worsening diabetes. Diabetes Care. 2007;30:263–9.

    Article  PubMed  Google Scholar 

  55. Riddle M, Umpierrez G, DiGenio A, Zhou R, Rosenstock J. Contributions of basal and postprandial hyperglycemia over a wide range of A1C levels before and after treatment intensification in type 2 diabetes. Diabetes Care. 2011;34:2508–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Freinkel N, Goodner CJ. Insulin metabolism and pregnancy. Arch Intern Med. 1962;109:235–44.

    Article  CAS  PubMed  Google Scholar 

  57. Freinkel N Banting lecture 1980. Of pregnancy and progeny. Diabetes. 1980;29:1023–35.

    Article  CAS  PubMed  Google Scholar 

  58. Hernandez TL, Friedman JE, van Pelt RE, Barbour LA. Patterns of glycemia in normal pregnancy: should the current therapeutic targets be challenged. Diabetes Care. 2011;34:1660–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. O’Connor C, O’Shea PM, Owens LA, et al. Trimester-specific reference intervals for hemoglobin A1c (HbA1c) in pregnancy. Clin Chem Lab Med. 2011;50:905–9.

    PubMed  Google Scholar 

  60. Blumer I, Hadar E, Hadden DR, Jovanovic L, Mestman JH, Murad MH, et al. Diabetes and pregnancy: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2013;98:4227–49.

    Article  CAS  PubMed  Google Scholar 

  61. Thompson D, Berger H, Feig D, Gagnon R, Kader T, Keely E, et al. Diabetes and pregnancy. Can J Diabetes. 2013;37Suppl 1: S168–83

  62. National Institute for Health and Care Excellence (NICE). Diabetes in pregnancy: management of diabetes and its complications from pre-conception to the postnatal period. 2008. Report 97. No.: CG63

  63. American Diabetes Association. Standards of medical care in diabetes–2015. Diabetes Care 2015;38Suppl 1:S77-S79

  64. Cheung NW, Conn JJ, d’Emden MC, Gunton JE, Jenkins AJ, Ross GP, et al. Position statement of the Australian Diabetes Society: individualization of glycatedhemoglobin targets for adults with diabetes mellitus. Med J Aust. 2009;191:339–44.

    PubMed  Google Scholar 

  65. Suhonen L, Hiilesmaa V, Teramo K. Glycemic control during early pregnancy and fetal malformations in women with type 1 diabetes mellitus. Diabetologia. 2000;43:79–82.

    Article  CAS  PubMed  Google Scholar 

  66. Guerin A, Nisenbaum R, Ray JG. Use of maternal GHb concentration to estimate the risk of congenital anomalies in the offspring of women with pre-pregnancy diabetes. Diabetes Care. 2007;30:1920–5.

    Article  CAS  PubMed  Google Scholar 

  67. Jensen DM, Korsholm R, Ovesen P, et al. Peri-conceptional A1c and risk of serious adverse pregnancy outcome in 933 women with type 1 diabetes. Diabetes Care. 2009;32:1046–8.

    Article  PubMed  PubMed Central  Google Scholar 

  68. Greene MF, Hare JW, Cloherty JP, Benacerraf BR, Soeldner JS. First trimester hemoglobin A1 and risk for major malformation and spontaneous abortion in diabetic pregnancy. Teratology. 1989;39:225–31.

    Article  CAS  PubMed  Google Scholar 

  69. Miodovnik M, Mimouni F, Tsang RC, Ammar E, Kaplan L, Siddiqi TA. Glycemic control and spontaneous abortion in insulin-dependent diabetic women. ObstetGynecol. 1986;68:366–9.

    CAS  Google Scholar 

  70. Mills JL, Simpson JL, Driscoll SG, Jovanovic-Peterson L, Van Allen M, Aarons JH, Metzger B, et al. Incidence of spontaneous abortion among normal women and insulin-dependent diabetic women whose pregnancies were identified within 21 days of conception. N Engl J Med. 1988;319:1617–23.

    Article  CAS  PubMed  Google Scholar 

  71. Jovanovic L, Knopp RH, Kim H, Cefalu WT, Simpson JL, Mills JL, et al. Elevated pregnancy losses at high and low extremes of maternal glucose in early normal and diabetic pregnancy. Diabetes Care. 2005;28:1113–7.

    Article  PubMed  Google Scholar 

  72. Damm P, Mersebach H, Rastam J, Kaaja R, et al. Poor pregnancy outcome in women with type 1 diabetes is predicted by elevated HbA1c and spikes of high glucose values in the third trimester. J Matern Fetal Neonatal Med. 2014;27:149–54.

    Article  CAS  PubMed  Google Scholar 

  73. Mello G, Parretti E, Mecacci F, La TP, Cioni R, Cianciulli D, et al. What degree of maternal metabolic control in women with type 1 diabetes is associated with normal body size and proportions in full-term infants? Diabetes Care. 2000;23:1494–8.

    Article  CAS  PubMed  Google Scholar 

  74. Combs CA, Gunderson E, Kitzmiller JL, Gavin LA, Main EK. Relationship of fetal macrosomia to maternal postprandial glucose control during pregnancy. Diabetes Care. 1992;15:1251–7.

    Article  CAS  PubMed  Google Scholar 

  75. Lind T, Cheyne GA. Effect of normal pregnancy upon the glycosylated hemoglobins. Br J Obstet Gynaecol. 1979;86:210–3.

    Article  CAS  PubMed  Google Scholar 

  76. Lurie S Age distribution of erythrocyte population in late pregnancy. Gynecol Obstet Investig. 1990;30:147–9.

    Article  CAS  Google Scholar 

  77. Lurie S, Danon D. Life span of erythrocytes in late pregnancy. Obstet Gynecol. 1992;80:123–6.

    CAS  PubMed  Google Scholar 

  78. Lurie S, Mamet Y. Red blood cell survival and kinetics during pregnancy. Eur J Obstet Gynecol Reprod Biol. 2000;93:185–92.

    Article  CAS  PubMed  Google Scholar 

  79. Evers IM, de Valk HW, Visser GHA. Risk of complications of pregnancy in women with type 1 diabetes: nationwide prospective study in the Netherlands. Br Med J. 2004;328:915–8.

    Article  Google Scholar 

  80. Jensen DM, Damm P, Moelsted-Pedersen L, et al. Outcomes in type 1 diabetic pregnancies: a nationwide, population-based study. Diabetes Care. 2004;27:2819–23.

    Article  PubMed  Google Scholar 

  81. Clausen TD, Mathiesen E, Ekbom P, Hellmuth E, Mandrup-Poulsen T, Damm P. Poor pregnancy outcome in women with type 2 diabetes. Diabetes Care. 2005;28:323–8.

    Article  PubMed  Google Scholar 

  82. Huddle KR. Audit of the outcome of pregnancy in diabetic women in Soweto, South Africa, 1992–2002. S Afr Med J. 2005;95:789–94.

    CAS  PubMed  Google Scholar 

  83. Roland JM, Murphy HR, Ball V, Northcote-Wright J, Temple RC. The pregnancies of women with type 2 diabetes: poor outcomes but opportunities for improvement. Diabet Med. 2005;22:1774–7.

    Article  CAS  PubMed  Google Scholar 

  84. Hillman Gadea N, Herranz L, Vaquero PM, Villarroel A, Fernandez A, Pallardo LF. Is pregnancy outcome worse in type 2 than in type 1 diabetic women? Diabetes Care. 2006;29:2557–8.

    Article  Google Scholar 

  85. Gimenez M, Conget I, Nicolau J, Pericot A, Levy I. Outcome of pregnancy in women with type 1 diabetes intensively treated with continuous subcutaneous insulin infusion or conventional therapy. A case-control study. Acta Diabetol. 2007;44:34–7.

    Article  CAS  PubMed  Google Scholar 

  86. Gonzalez-Gonzalez NL, Ramirez O, Mozas J, et al. Factors influencing pregnancy outcome in women with type 2 versus type 1 diabetes mellitus. Acta Obstetriciaet Gynecologica Scandinavica. 2008;87:43–9.

    Article  Google Scholar 

  87. Murphy HR, Steel SA, Roland JM, et al. Obstetric and perinatal outcomes in pregnancies complicated by type1 and type2 diabetes: influences of glycaemic control, obesity and social disadvantage. Diabet Med. 2011;28:1060–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Owens LA, Avalos G, Kirwan B, Carmody L, Dunne F. Atlantic dip. Closing the loop. Diabetes Care. 2012;35:1669–71.

    Article  PubMed  PubMed Central  Google Scholar 

  89. deValk HW, van Nieuwaal NH, Visser GH. Pregnancy outcome in type 2 diabetes mellitus: a retrospective analysis from the Netherlands. The Review of Diabetic Studies. 2006;3:134–42.

    Article  Google Scholar 

  90. Langer O, Conway DL, Berkus MD, Gonzales O, et al. A comparison of glyburide and insulin in women with gestational diabetes mellitus. N Engl J Med. 2000;343:1134–8.

    Article  CAS  PubMed  Google Scholar 

  91. Rowan JA, Hague WM, Gao W, Battin MR, Moore MP, et al. Metformin versus insulin for the treatment of gestational diabetes. N Engl J Med. 2008;358:2003–15.

    Article  CAS  PubMed  Google Scholar 

  92. Metzger BE, Lowe LP, Dyer AR, Trimble ER, et al. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med. 2008;358:1991–2002.

    Article  PubMed  Google Scholar 

  93. Prutsky GJ, Domecq JP, Wang Z, Carranza Leon BG, Elraiyah T, Nabhan M, et al. Glucose targets in pregnant women with diabetes: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2013;98:4319–24.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Endocrinology, Diabetes and Metabolism, Jaslok Hospital and Research Centre and Dr. Chandalia’s Diabetes Endocrine Nutrition Management and Research Centre, Mumbai, India

    Hemraj B. Chandalia

  2. Diabetes Endocrine Nutrition Management and Research Centre, Mumbai, India

    Puja M. Thadani

Authors
  1. Hemraj B. Chandalia
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Puja M. Thadani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hemraj B. Chandalia.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chandalia, H.B., Thadani, P.M. Glycemic targets in diabetes. Int J Diabetes Dev Ctries 36, 359–369 (2016). https://doi.org/10.1007/s13410-016-0467-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13410-016-0467-8

Keywords

Search

Navigation